The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.

PS Sever; NR Poulter; B Dahlof; H Wedel; G Beevers; M Caulfield; R Collins; SE Kjeldsen; A Kristinsson; G McInnes; J Mehlsen; MS Nieminen; ET O'Brien; J Ostergren

doi:10.1093/eurheartj/ehm583

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.

PS Sever, NR Poulter, B Dahlof, H Wedel, G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson, G McInnes, J Mehlsen, MS Nieminen, ET O'Brien, J Ostergren

Landspitali - The National University Hospital of Iceland

Research output: Contribution to journal › Article › peer-review

Abstract

Aims To determine the cardiovascular benefits in those originally assigned atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-2.2 years after closure of the lipid-lowering arm of the trial (ASCOT-LLA). Methods and results The Blood Pressure Lowering Arm of the ASCOT trial (ASCOT-BPLA) compared two different antihypertensive treatment strategies on cardiovascular outcomes. ASCOT-LLA was a double-blind placebo-controlled trial of atorvastatin in those enrolled into ASCOT-BPLA with total cholesterol concentrations at baseline of

Original language	English
Journal	European Heart Journal
DOIs	https://doi.org/10.1093/eurheartj/ehm583
Publication status	Published - 1 Feb 2008

Access to Document

10.1093/eurheartj/ehm583

http://eurheartj.oxfordjournals.org/cgi/content/abstract/29/4/499

Cite this

Sever, PS., Poulter, NR., Dahlof, B., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, SE., Kristinsson, A., McInnes, G., Mehlsen, J., Nieminen, MS., O'Brien, ET., & Ostergren, J. (2008). The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European Heart Journal. https://doi.org/10.1093/eurheartj/ehm583

@article{cc29e1d40b72424ca272b85c975c6ca2,

title = "The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.",

abstract = "Aims To determine the cardiovascular benefits in those originally assigned atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-2.2 years after closure of the lipid-lowering arm of the trial (ASCOT-LLA). Methods and results The Blood Pressure Lowering Arm of the ASCOT trial (ASCOT-BPLA) compared two different antihypertensive treatment strategies on cardiovascular outcomes. ASCOT-LLA was a double-blind placebo-controlled trial of atorvastatin in those enrolled into ASCOT-BPLA with total cholesterol concentrations at baseline of",

author = "PS Sever and NR Poulter and B Dahlof and H Wedel and G Beevers and M Caulfield and R Collins and SE Kjeldsen and A Kristinsson and G McInnes and J Mehlsen and MS Nieminen and ET O'Brien and J Ostergren",

year = "2008",

month = feb,

day = "1",

doi = "10.1093/eurheartj/ehm583",

language = "English",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.

AU - Sever, PS

AU - Poulter, NR

AU - Dahlof, B

AU - Wedel, H

AU - Beevers, G

AU - Caulfield, M

AU - Collins, R

AU - Kjeldsen, SE

AU - Kristinsson, A

AU - McInnes, G

AU - Mehlsen, J

AU - Nieminen, MS

AU - O'Brien, ET

AU - Ostergren, J

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Aims To determine the cardiovascular benefits in those originally assigned atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-2.2 years after closure of the lipid-lowering arm of the trial (ASCOT-LLA). Methods and results The Blood Pressure Lowering Arm of the ASCOT trial (ASCOT-BPLA) compared two different antihypertensive treatment strategies on cardiovascular outcomes. ASCOT-LLA was a double-blind placebo-controlled trial of atorvastatin in those enrolled into ASCOT-BPLA with total cholesterol concentrations at baseline of

AB - Aims To determine the cardiovascular benefits in those originally assigned atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-2.2 years after closure of the lipid-lowering arm of the trial (ASCOT-LLA). Methods and results The Blood Pressure Lowering Arm of the ASCOT trial (ASCOT-BPLA) compared two different antihypertensive treatment strategies on cardiovascular outcomes. ASCOT-LLA was a double-blind placebo-controlled trial of atorvastatin in those enrolled into ASCOT-BPLA with total cholesterol concentrations at baseline of

U2 - 10.1093/eurheartj/ehm583

DO - 10.1093/eurheartj/ehm583

M3 - Article

C2 - 18175773

SN - 0195-668X

JO - European Heart Journal

JF - European Heart Journal

ER -

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.

Abstract

Access to Document

Fingerprint

Cite this